Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • International Physiotherapy Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Other Guidelines

Response to oral antibiotic treatment in people with cystic fibrosis

  • Read more about Response to oral antibiotic treatment in people with cystic fibrosis

Molecular fingerprinting of Pseudomonas aeruginosa from PWCF, and a UK reference laboratory investigation into frequency of cross-infection

  • Read more about Molecular fingerprinting of Pseudomonas aeruginosa from PWCF, and a UK reference laboratory investigation into frequency of cross-infection

Ivacaftor impacts nutrition and growth status in 4 to 24 month old children within the first 12 weeks

  • Read more about Ivacaftor impacts nutrition and growth status in 4 to 24 month old children within the first 12 weeks

Year in Review (2022): Modulators and COVID-19: the story does on

  • Read more about Year in Review (2022): Modulators and COVID-19: the story does on

Successful treatment of a blockage in the lower portion of the small intestine in patients with cystic fibrosis using a solution administered during a colonoscopy.

  • Read more about Successful treatment of a blockage in the lower portion of the small intestine in patients with cystic fibrosis using a solution administered during a colonoscopy.

Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis

  • Read more about Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis

Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

  • Read more about Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

  • Read more about Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

  • Read more about Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

Effects of elexacaftor/tezacaftor/ivacaftor on liver tests in cystic fibrosis

  • Read more about Effects of elexacaftor/tezacaftor/ivacaftor on liver tests in cystic fibrosis
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2023. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)